Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced that it has begun patient dosing in a Phase I trial of its novel, orally active agent NRX-1074.

More here:
Naurex initiates Phase I trial of NRX-1074 in normal volunteers

Scroll to Top